- Home
- CLDI
as 12-20-2024 4:00pm EST
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 18.1M | IPO Year: | N/A |
| Target Price: | $16.67 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.14 - $3.89 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Calidi Biotherapeutics Inc. News
CLDI Breaking Stock News: Dive into CLDI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
GlobeNewswire
a month ago
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
GlobeNewswire
a month ago
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
GlobeNewswire
a month ago
Calidi Biotherapeutics Announces Proposed Public Offering
GlobeNewswire
a month ago
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
ACCESSWIRE
2 months ago
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
TipRanks
2 months ago
Calidi to sell 2.05M shares at $1.00 in registered direct offering
GlobeNewswire
2 months ago
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
Compare CLDI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDI Calidi Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.